Adaptimmune Therapeutics
Adaptimmune Therapeutics44
About
What does Adaptimmune Therapeutics do?
Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company focused on developing and delivering novel T-cell therapies for cancer. They utilize a proprietary T-cell receptor (TCR) platform to engineer T-cells that can identify and target cancer cells, aiming to significantly impact cancer treatment outcomes. Their pipeline includes therapies for various solid tumor types.
What is Adaptimmune Therapeutics's revenue?
StartupHub estimates Adaptimmune Therapeutics's annual revenue at $28.3M (range $15.9M to $79.6M, 68% confidence), based on comparable companies in the sector.
What is Adaptimmune Therapeutics's valuation?
StartupHub estimates Adaptimmune Therapeutics's effective valuation at $1.1B (range $419.9M to $2.0B, 43% confidence), based on comparable companies in the sector.
How much funding has Adaptimmune Therapeutics raised?
Adaptimmune Therapeutics has raised a total of $107M in funding. The most recent round on record is Series A.
Where is Adaptimmune Therapeutics headquartered?
Adaptimmune Therapeutics is headquartered in Abingdon, United Kingdom.
When was Adaptimmune Therapeutics founded?
Adaptimmune Therapeutics was founded in 2008.
What industry does Adaptimmune Therapeutics operate in?
Adaptimmune Therapeutics operates in Biotechnology, Pharmaceuticals, Drug Discovery, Cancer Immunotherapy, Cell Therapy, Oncology.
How many employees does Adaptimmune Therapeutics have?
Adaptimmune Therapeutics has approximately 191 people on record.
No comments yet. Be the first to share your take.